The laboratory of Dr. Moldoneavu centers on utilizing structural and biochemical approaches to understand the mechanisms of programmed cell death including apoptosis, necroptosis, and ferroptosis particularly in myeloma.
Yunmeng Liu, Ph.D.
Amit K. Tiwari, Ph.D., D.A.B.T
Tudor Moldoneavu, Ph.D.
Dan Dixon, Ph.D.
Sanja Novak, Ph.D.
Tuhin Virmani, M.D., Ph.D.
The research interests of the Virmani laboratory are: 1) the development of predictive algorithms for disease progression in Parkinson’s disease with Freezing of Gait as a model system; 2) the development of treatments for Freezing of Gait; 3) improving care delivery (such as through a hub-and-spoke model of clinical care) and increasing research participation for […]
Mokarram Hossain, PhD
My laboratory develops novel immunotherapies for rare solid tumors and inflammatory conditions. We engineer therapeutic antibodies with two key goals: harnessing immune cells’ natural ability to destroy cancer and blocking specific receptors to control inflammation. Our mission is to advance these novel treatments to the clinic, particularly focusing on rare disease patients who have limited […]
Michael Bauer, Ph.D.
Dr. Bauer’s research interests include cancer genomics and integration of heterogenous datasets in multiple myeloma and investigating cancer disparities in minority and rural populations.
Brian Koss, Ph.D.
Dr. Koss’s research interests are focused on understanding the fundamental mechanisms T cells utilize to adapt to environmental stress. His laboratory is currently developing and applying cutting-edge proteomic approaches to elucidate how proteome turnover dynamics influence the ability of a T cell to persist in solid tumors. To translate these findings, his laboratory seeks to […]